- Home
- SDGR
SDGR
Schrodinger Inc.
as 12-18-2024 11:42am EST
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
| Founded: | 1990 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 1.6B | IPO Year: | 2020 |
| Target Price: | $32.90 | AVG Volume (30 days): | 594.0K |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $16.67 - $38.00 | Next Earning Date: | 11-12-2024 |
| Revenue: | $193,348,000 | Revenue Growth: | -3.03% |
| Revenue Growth (this year): | -4.6% | Revenue Growth (next year): | 26.50% |
Stock Insider Trading Activity of Schrodinger Inc. (SDGR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dugan Margaret | SDGR | Chief Medical Officer | Oct 15 '24 | Sell | $17.78 | 1,531 | $27,225.77 | 13,469 |
Latest Schrodinger Inc. News
SDGR Breaking Stock News: Dive into SDGR Ticker-Specific Updates for Smart Investing
Business Wire
a day ago
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Argus Research
8 days ago
SDGR: What does Argus have to say about SDGR?
Argus Research
15 days ago
SDGR: Raising target price to $18.00
Business Wire
a month ago
Schrödinger to Present at Piper Sandler 36th Annual Healthcare Conference
Business Wire
a month ago
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Business Wire
a month ago
Schrödinger Broadens and Accelerates Predictive Toxicology Initiative
Simply Wall St.
a month ago
Schrödinger Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
TipRanks
a month ago
Schrodinger announces expanded license agreement with Novartis
Compare SDGR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SDGR Schrodinger Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.